Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30713090 | 1.00 | MAPT (0.76) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL26127049 | 0.99 | MAPT (0.74) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30254421 | 0.88 | MAPT (0.58) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30147326 | 0.88 | MAPT (0.58) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL595690 | 0.87 | MAPT (1.00) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL21604946 | 0.84 | MAPT (0.78) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27171649 | 0.82 | MAPT (0.70) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26125690 | 0.82 | MAPT (0.69) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL21605124 | 0.81 | TRPC1 (0.58) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30147834 | 0.81 | TRPC1 (0.58) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-12-26 | — | — | US | disclosed |
| US-20240317739-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-26 | — | — | US | disclosed |
| EP-4349825-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4339196-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-03-20 | — | — | EP | disclosed |
| CN-117500804-A | Novel urea derivative compounds as RON inhibitors | 株式会社LG化学 | 2024-02-02 | — | — | CN | disclosed |
| CN-112601747-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | MAPT 4760/4885POLB 3979/4885SMN1; SMN2 1771/4885 |
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | RET, MST1R, ROS1 | MAPT 4286/4885POLB 4572/4885SMN1; SMN2 4129/4885 |
| US-20240317739-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | CDKN1A, RET, UBTF | MAPT 2721/4885POLB 3957/4885SMN1; SMN2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.